Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high ...

A single daily preventer dose of inhaled corticosteroid (beclomethasone), taken at mid-afternoon, may be the best timing for ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy ...

Inhaled corticosteroids are often used outside of the recommended indications in COPD. Researchers revealed a link between long-term use and several risks for new diagnoses. Adults with COPD who ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium ... to relieve symptoms in adults with COPD. Bevespi, which is taken twice daily, is part of a new generation of medicines that ...

A single daily preventive dose of inhaled corticosteroid is best taken at mid-afternoon for effective asthma control, researchers reported April 15 in the journal Thorax. That timing will suppress ...

Background and goal: Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have asthma ...

Experts say the findings, published in the journal Thorax, are the first to show the importance of using the inhaler with best effect for ... They also trialled a once-daily dose of 400mg between ...

Inhalers may be prescribed to people who have a variety of health conditions both chronic and acute, including asthma, chronic obstructive pulmonary ... doing this daily or after a few usages ...

QVM149 is a triple therapy consisting of indacaterol (acetate), glycopyrronium (bromide) and mometasone (furoate), which is being developed as a daily inhaled treatment for asthma delivered via ...

Symptoms include persistent cough, excessive mucus production, and shortness of breath that may impair the ability to perform routine daily ... inhaled particles are key risk factors for COPD ...